196 related articles for article (PubMed ID: 14593855)
21. Topoisomerase I inhibition: a new target or new missiles?
Verweij J; Schellens JH
Ann Oncol; 1995 Feb; 6(2):102-4. PubMed ID: 7786815
[No Abstract] [Full Text] [Related]
22. An overview of topoisomerase I-targeting agents.
Arbuck SG; Takimoto CH
Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
[TBL] [Abstract][Full Text] [Related]
23. Clinical pharmacology and pharmacodynamics of irinotecan. A review.
Chabot GG
Ann N Y Acad Sci; 1996 Dec; 803():164-72. PubMed ID: 8993509
[No Abstract] [Full Text] [Related]
24. Topoisomerase I inhibitors: review and update.
Rothenberg ML
Ann Oncol; 1997 Sep; 8(9):837-55. PubMed ID: 9358934
[TBL] [Abstract][Full Text] [Related]
25. Topoisomerase-I inhibitors in the management of colon cancer.
Willson JK
Ann N Y Acad Sci; 1996 Dec; 803():256-63. PubMed ID: 8993519
[No Abstract] [Full Text] [Related]
26. DNA topoisomerase I poisons.
Takimoto CH; Kieffer LV; Kieffer ME; Arbuck SG; Wright J
Cancer Chemother Biol Response Modif; 1999; 18():81-124. PubMed ID: 10800479
[No Abstract] [Full Text] [Related]
27. [Pharmacology of camptothecin and its derivatives].
Rivory LP; Robert J
Bull Cancer; 1995 Apr; 82(4):265-85. PubMed ID: 10846537
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of resistance to camptothecins.
Saleem A; Edwards TK; Rasheed Z; Rubin EH
Ann N Y Acad Sci; 2000; 922():46-55. PubMed ID: 11193924
[TBL] [Abstract][Full Text] [Related]
29. Camptothecins: new enthusiasm for an old drug.
Rowe PM
Lancet; 1996 Mar; 347(9005):892. PubMed ID: 8622402
[No Abstract] [Full Text] [Related]
30. [Irinotecan chemotherapy for patients with advanced or relapsed pancreatic neoplasm].
Sekikawa T; Akaike A; Ushio J; Sato A; Matsukawa M
Nihon Rinsho; 2006 Jan; 64 Suppl 1():203-6. PubMed ID: 16457250
[No Abstract] [Full Text] [Related]
31. [Current status of camptothecin derivatives as natural antitumor agents].
Pan XD; Wang CY
Yao Xue Xue Bao; 2003 Sep; 38(9):715-20. PubMed ID: 14730926
[No Abstract] [Full Text] [Related]
32. Clinical pharmacokinetics of irinotecan.
Chabot GG
Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
[TBL] [Abstract][Full Text] [Related]
33. FDA approves irinotecan as first-line therapy for colorectal cancer.
Oncology (Williston Park); 2000 May; 14(5):652, 654. PubMed ID: 10853457
[No Abstract] [Full Text] [Related]
34. Irinotecan for metastatic colorectal cancer.
Med Lett Drugs Ther; 1997 Jan; 39(992):8. PubMed ID: 9008684
[No Abstract] [Full Text] [Related]
35. [CPT-11 (irinotecan)--evidence from molecular and pharmacological studies and clinical applications].
Isobe T; Ishikawa N; Oguri T
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1267-78. PubMed ID: 10945026
[TBL] [Abstract][Full Text] [Related]
36. Irinotecan (CPT-11): pharmacology and clinical applications.
Masuda N; Kudoh S; Fukuoka M
Crit Rev Oncol Hematol; 1996 Sep; 24(1):3-26. PubMed ID: 8869796
[No Abstract] [Full Text] [Related]
37. [Irinotecan in colorectal cancer].
Pozzo C; Cassano A; Barone C
Tumori; 2001; 87(1 Suppl 1):S49-50. PubMed ID: 11300023
[No Abstract] [Full Text] [Related]
38. Review camptothecin: current perspectives.
Li QY; Zu YG; Shi RZ; Yao LP
Curr Med Chem; 2006; 13(17):2021-39. PubMed ID: 16842195
[TBL] [Abstract][Full Text] [Related]
39. [Homocamptothecins--novel promising anticancer drugs as inhibitors of topoisomerase I].
Yang S; Zhang WN
Yao Xue Xue Bao; 2004 May; 39(5):396-400. PubMed ID: 15338888
[No Abstract] [Full Text] [Related]
40. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.
Hartmann JT; Lipp HP
Drug Saf; 2006; 29(3):209-30. PubMed ID: 16524321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]